All In Biotech

Drug Trial Radar · NCT07478744

A Phase 2a Efficacy, Safety, Tolerability, and PK Study of SYT-510 in Participants With Generalized Anxiety Disorder

A Study Investigating the Efficacy, Safety, Tolerability, and Pharmacokinetics of a Single Dose of SYT-510 in Participants Who Meet DSM-5 Diagnostic Criteria for Generalized Anxiety Disorder

Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Apr 22, 2026

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
Synendos Therapeutics AGIndustry
Sponsor type
Industry
First posted
Mar 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single dose study to investigate the efficacy, safety, tolerability and the PK, of SYT-510 in participants who meet diagnostic criteria of GAD. This study represents an evaluation of the effects of SYT-510 in participants meeting DSM-5 GAD diagnostic criteria. As a single dose study, it is designed to evaluate the efficacy of SYT-510 on neurobiological and behavioral markers associated with anxiety and will inform the design of future clinical trials in anxiety disorders. By integrating efficacy / PD, safety, tolerability, and PK measures within the same study framework, the study enables the translational value of the program, ensuring a more comprehensive understanding of SYT-510 effects in patients with generalized anxiety disorders. The plan is to evaluate a single dose of SYT-510 as compared with its matching placebo in a two-way crossover design, separated by a washout period of 7 to 14 days.

Conditions

  • Generalized Anxiety Disorder

Interventions

  • SYT-510Drug

    SYT-510 will be administered as a single oral dose in the morning with liquid.

  • PlaceboDrug

    Matching placebo will be administered as a single oral dose in the morning with liquid.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. BOLD fMRI signal in the amygdala in response to fearful stimuliTime frame: 7 hours post-dose on Day 2 Treatment period 1 and Day 2 Treatment period 2
  2. Defensive behavior: Joystick Operated Runway Task (JORT) Flight IntensityTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
  3. Defensive behavior: Joystick Operated Runway Task Risk Assessment IntensityTime frame: 4 hours post-dose, Day 2 Treatment Period 1 and Day 2 Treatment period 2
  4. Subjective dread during Joystick Operated Runway Task (JORT)Time frame: 4 hours post-dose, Day 2 Treatment Period 1 and Day 2 Treatment period 2
  5. Approach-avoidance learning: reward-punishment sensitivity indexTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
  6. Approach-avoidance learning: punishment sensitivity indexTime frame: 4 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
  7. Default Mode Network connectivity (fMRI)Time frame: 7 hours post dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
  8. Reaction time to fearful faces (fMRI task)Time frame: 7 hours post-dose, Day 2 Treatment period 1 and Day 2 Treatment period 2
  9. Self reported State Trait Anxiety Inventory (STAI) subscale scoreTime frame: 1 day post-dose, on Day 3 Treatment period 1 and Day 3 treatment period 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • SLaM

    London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.